Genmab A/S
GMAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,022 | $5,862 | $715 | $6,441 |
| % Growth | -82.6% | 719.8% | -88.9% | – |
| Cost of Goods Sold | $58 | $361 | $42 | $337 |
| Gross Profit | $964 | $5,501 | $673 | $6,104 |
| % Margin | 94.3% | 93.8% | 94.1% | 94.8% |
| R&D Expenses | $357 | $2,307 | $359 | $2,664 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $148 | $913 | $126 | $1,249 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $31 |
| Operating Expenses | $505 | $3,219 | $485 | $3,944 |
| Operating Income | $459 | $2,281 | $188 | $2,160 |
| % Margin | 44.9% | 38.9% | 26.3% | 33.5% |
| Other Income/Exp. Net | $23 | $399 | $56 | $1,442 |
| Pre-Tax Income | $482 | $2,681 | $244 | $3,602 |
| Tax Expense | $81 | $551 | $49 | -$243 |
| Net Income | $401 | $2,129 | $195 | $3,845 |
| % Margin | 39.2% | 36.3% | 27.3% | 59.7% |
| EPS | 0.65 | 3.45 | 0.31 | 5.99 |
| % Growth | -81.2% | 1,012.9% | -94.8% | – |
| EPS Diluted | 0.65 | 3.42 | 0.31 | 5.99 |
| Weighted Avg Shares Out | 616 | 618 | 637 | 642 |
| Weighted Avg Shares Out Dil | 621 | 620 | 639 | 642 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32 | $158 | $33 | $224 |
| Interest Expense | $3 | $57 | $5 | $54 |
| Depreciation & Amortization | $18 | $101 | $16 | $88 |
| EBITDA | $503 | $2,839 | $265 | $2,355 |
| % Margin | 49.2% | 48.4% | 37.1% | 36.6% |